A 73-year-old woman died after developing a fatal bowel perforation shortly after increasing her dose of the weight-loss drug Mounjaro.
A UK inquest is now examining whether the medication's gastrointestinal effects contributed to a delayed diagnosis of a medical emergency.
Caroline Savage, a mother and grandmother from Norfolk, England, had been taking Mounjaro for about four months before she became seriously ill in October 2024.
The inquest is investigating whether her symptoms were linked to the medication or whether concerns about common drug side effects influenced how doctors assessed her condition.
The case has raised new questions about how clinicians evaluate severe abdominal pain in patients using popular GLP-1 medications, which have seen rapidly increasing use for weight management.
Sudden Pain After Mounjaro Dose Increase
Savage began taking Mounjaro after seeking help with weight loss and conditions including lipoedema and lymphoedema. She was prescribed the medication privately after weighing 128 kilograms, with a body mass index of 46.
According to evidence presented at the inquest, Savage had been responding well to treatment and had lost weight before being advised to increase her dose from 7.5 milligrams to 10 milligrams.
She was taken by ambulance to Norfolk and Noweich University Hospital, where doctors considered possible causes, including pancreatitis, a rare but recognized complication associated with some weight-loss medications.
However, tests did not indicate pancreatitis, and medical staff determined she did not require admission or further imaging at that time.
Family Questions Whether Warning Signs Were Missed
Savage was discharged from the hospital later that evening with pain relief and advice but collapsed at home hours later.
Despite emergency efforts, she died.
A postmortem examination found she had died from fecal peritonitis, a severe infection caused by intestinal contents leaking into the abdominal cavity after part of her bowel perforated.
Her family has questioned whether more investigations, including a CT scan or surgical review, should have been carried out before she was sent home.
They argued that her symptoms may have been incorrectly attributed to expected Mounjaro side effects, including abdominal pain and digestive problems.
Possible Drug Connection
The inquest heard that there is currently no established evidence directly proving Mounjaro causes bowel perforation.
However, medical experts discussed whether the medication's effects on the digestive system could have contributed to the situation. Mounjaro, also known by its generic name tirzepatide, slows the movement of food through the stomach and intestines, which can cause gastrointestinal symptoms such as constipation.
The hearing considered whether those effects could increase pressure in the intestines in someone with an existing condition such as diverticular disease, potentially increasing the risk of complications. Experts said any possible contribution would be difficult to measure.
Doctors who treated Savage said her examination findings, blood tests and ultrasound results appeared reassuring at the time and that diverticular perforation can be difficult to predict.
Mounjaro and other GLP-1 medications have transformed obesity treatment, but their rapid rise has also increased attention on potential complications and how healthcare providers assess patients experiencing severe symptoms.
The inquest comes as millions of people worldwide use injectable weight-loss medications, making questions around side effects, monitoring, and emergency decision-making increasingly important.
The coroner is yet to issue a final conclusion on Savage's death. Further findings will determine whether the medication, medical decision-making or other factors played a role in the fatal outcome.
